Tandem Diabetes Care, Inc. (TNDM)

Market Cap	1.98B
Revenue (ttm)	854.35M
Net Income (ttm)	-126.78M
Shares Out	65.68M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,002,280
Open	28.03
Previous Close	27.87
Day's Range	27.40 - 30.33
52-Week Range	18.42 - 53.69
Beta	1.37
Analysts	Buy
Price Target	52.50 (+74.13%)
Earnings Date	Nov 6, 2024

About TNDM

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and deliverin...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 14, 2013
• Employees: 2,400
• Stock Exchange: NASDAQ
• Ticker Symbol: TNDM
• Website: https://www.tandemdiabetes.com

Financial Performance

In 2023, Tandem Diabetes Care's revenue was $747.72 million, a decrease of -6.68% compared to the previous year's $801.22 million. Losses were -$222.61 million, 135.3% more than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price forecast is $52.5, which is an increase of 74.13% from the latest price.

Price Target

$52.5

(74.13% upside)

Analyst Consensus: Buy